Previous Page  12 / 49 Next Page
Show Menu
Previous Page 12 / 49 Next Page
Page Background


Care and research are well integrated on a daily basis, and many high-level basic and

translational research teams are dedicated to paediatric malignancies.


Approximately 350 European public specialised centres in paediatric university hospitals

and comprehensive cancer centres take care of patients with a paediatric cancer, and

private practice is extremely rare.


There is a strong awareness of the needs and challenges for childhood cancer survivors,

with dedicated groups (e.g. PanCare, the Pan-European network for Care of survivors

after childhood and adolescent cancer) encompassing both healthcare professionals

and survivors.


Most clinical trials are run at the European level for each malignancy by well-organized

European Clinical Trial Groups (ECTGs).


Up to 90% of newly diagnosed patients are treated according to standard protocols

or in prospective clinical trials. Up to 40% of patients are treated within therapeutic trials,

both at diagnosis or at relapse, and clinical research is mainly led by academia, with

industry-sponsored trials representing less than 5% of biomedical research.


The paediatric haematology-oncology community is accustomed to working together

since more than 50 years, with a strong track record of publishing peer reviewed research.

Though the area of paediatric haematology-

oncology is small, it is extremely complex

and covers at least 60 different types of

cancer in a population ranging from new-

borns to teenagers, and even more when

biological markers (“biomarkers”) are

considered [6].


Paediatric haematology-oncology

in Europe



Credit Israel Society of Pediatric Hematology and Oncology (ISPHO), Israel